Last update: Dec. 8, 2017

Ertapenem Sodium

Very Low Risk for breastfeeding


Safe. Compatible.
Not risky for breastfeeding or infant.

Antibacterial carbapenem beta-lactam with indications similar to imipenem.
Intravenous administration a daily dose.

It is excreted in breast milk in a clinically insignificant amount (Merck 2012).

Authorized pediatric use in infants from 3 months of age.

Its low oral bioavailability would make it difficult for it to pass to the infant’s plasma ingesting breast milk, except in preterm infants and in the immediate neonatal period when there may be increased intestinal permeability.

The possible negativity of cultures in febrile infants whose mothers take antibiotics should be taken into account, as well as the possibility of gastroenteritis due to altered intestinal flora (Benyamini 2005, Ito 1993, Kafetzis 1981).

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Group

Ertapenem Sodium belongs to this group or family:

Tradenames

Main tradenames from several countries containing Ertapenem Sodium in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. Baja - Poor %
Molecular weight 498 daltons
Protein Binding 95 %
VD 0,11 l/Kg
pKa 4,05 -
Tmax 0,5 hours
T1/2 4 hours
Theoretical Dose 0,057 mg/Kg/d
Relative Dose 0,34 %

References

  1. EMA. Ertapenem. Ficha técnica. 2017 Full text (in our servers)
  2. Merck. Ertapenem. Drug Summary. 2012 Full text (in our servers)
  3. Benyamini L, Merlob P, Stahl B, Braunstein R, Bortnik O, Bulkowstein M, Zimmerman D, Berkovitch M. The safety of amoxicillin/clavulanic acid and cefuroxime during lactation. Ther Drug Monit. 2005 Abstract
  4. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993 May;168(5):1393-9. Abstract
  5. Kafetzis DA, Siafas CA, Georgakopoulos PA, Papadatos CJ. Passage of cephalosporins and amoxicillin into the breast milk. Acta Paediatr Scand. 1981 Abstract

Total visits

5,374

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Instituto de Salud Infantil, Grecia-Institute of Child's Health in Greece

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM